Allegra Sales Slowdown Illustrates Shrinking Rx Allergy Market
This article was originally published in The Tan Sheet
Executive Summary
The closing of the Sanofi-Aventis merger - coupled with another consecutive quarter of declining Allegra (fexofenadine) sales - could accelerate a decision on whether to license out marketing rights to the prescription antihistamine